A affected person advocacy group is suing the Trump administration for failing to reveal particulars of a latest settlement with Gilead Sciences over the patent rights to a pair of HIV prevention capsules.
The deal, which was reached final January, capped a number of years of litigation that started when the Facilities for Illness Management and Prevention argued that it had funded essential tutorial analysis into HIV prevention that later fashioned the premise for the extremely efficient capsules, and that Gilead subsequently infringed its patent rights.
The case was intently watched as a result of it raised questions concerning the extent to which government-funded analysis ought to result in affordably priced medicines, since affected person advocates complained Gilead charged excessive costs for the capsules — Truvada and a more recent, upgraded model known as Descovy. The lawsuit raised a difficulty that, at occasions, figured within the bigger debate within the U.S. over the rising price of prescribed drugs.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
